Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter L Anderson

Showing results (21-30 of 270) with videos related to

Pageof 27
Sort By:
Current HIV/AIDS Reports|August 11, 2005
Therapeutic drug monitoring: pharmacologic considerations for antiretroviral drugsJennifer J Kiser, Peter L Anderson, John G Gerber
Current Opinion in HIV and AIDS|December 4, 2015
Nondaily preexposure prophylaxis for HIV preventionPeter L Anderson, J Gerardo García-Lerma, Walid Heneine
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 16, 2023
Reply to Niu and DrainPeter L Anderson, Mark A Marzinke, David V Glidden
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 16, 2023
Updating the Adherence-Response for Oral Emtricitabine/Tenofovir Disoproxil Fumarate for Human Immunodeficiency Virus Pre-Exposure Prophylaxis Among Cisgender WomenPeter L Anderson, Mark A Marzinke, David V Glidden
The Lancet. HIV|August 27, 2016
Pharmacology supports on-demand PrEPDavid V Glidden, Peter L Anderson, Robert M Grant
Expert Opinion on Pharmacotherapy|January 26, 2006
6th International Workshop on Clinical Pharmacology of HIV TherapyJennifer J Kiser, Peter L Anderson, Thomas N Kakuda
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 27, 2004
The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicitiesPeter L Anderson, Thomas N Kakuda, Kenneth A Lichtenstein
Therapeutic Advances in Infectious Disease|May 26, 2021
Beyond HIV viral load: application of pharmacologic measures to identify ART adherence mismatchMichael Kristofich, Peter L Anderson, Jose R Castillo-Mancilla
The Journal of Antimicrobial Chemotherapy|June 24, 2008
Cytokine and sex hormone effects on zidovudine- and lamivudine-triphosphate concentrations in vitroPeter L Anderson, Tracy King, Jia-Hua Zheng, et al.
AIDS (London, England)|October 3, 2003
Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individualsPeter L Anderson, Thomas N Kakuda, Sagar Kawle, et al.
Pageof 27

Showing results (21-30 of 270) with videos related to

Sort By:
Pageof 27
Current HIV/AIDS Reports|August 11, 2005
Therapeutic drug monitoring: pharmacologic considerations for antiretroviral drugsJennifer J Kiser, Peter L Anderson, John G Gerber
Current Opinion in HIV and AIDS|December 4, 2015
Nondaily preexposure prophylaxis for HIV preventionPeter L Anderson, J Gerardo García-Lerma, Walid Heneine
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 16, 2023
Reply to Niu and DrainPeter L Anderson, Mark A Marzinke, David V Glidden
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 16, 2023
Updating the Adherence-Response for Oral Emtricitabine/Tenofovir Disoproxil Fumarate for Human Immunodeficiency Virus Pre-Exposure Prophylaxis Among Cisgender WomenPeter L Anderson, Mark A Marzinke, David V Glidden
The Lancet. HIV|August 27, 2016
Pharmacology supports on-demand PrEPDavid V Glidden, Peter L Anderson, Robert M Grant
Expert Opinion on Pharmacotherapy|January 26, 2006
6th International Workshop on Clinical Pharmacology of HIV TherapyJennifer J Kiser, Peter L Anderson, Thomas N Kakuda
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 27, 2004
The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicitiesPeter L Anderson, Thomas N Kakuda, Kenneth A Lichtenstein
Therapeutic Advances in Infectious Disease|May 26, 2021
Beyond HIV viral load: application of pharmacologic measures to identify ART adherence mismatchMichael Kristofich, Peter L Anderson, Jose R Castillo-Mancilla
The Journal of Antimicrobial Chemotherapy|June 24, 2008
Cytokine and sex hormone effects on zidovudine- and lamivudine-triphosphate concentrations in vitroPeter L Anderson, Tracy King, Jia-Hua Zheng, et al.
AIDS (London, England)|October 3, 2003
Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individualsPeter L Anderson, Thomas N Kakuda, Sagar Kawle, et al.
Pageof 27